Preeclampsia Market Size Set for Steady Growth Across 7MM, Reaching USD 116 Million at a CAGR of 3.30% by 2036

The Preeclampsia market size across the 7MM is projected to increase from USD 87 million in 2025 to USD 116 million by 2036. It is anticipated to expand at a CAGR of 3.30% through 2036 across major regions, including the US, EU4, the UK, and Japan. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Preeclampsia landscape.

The overall Preeclampsia market size across the 7MM was predominantly driven by the United States, which held the largest share at approximately USD 70 million in 2024. Within Europe, Germany and France led the EU4 and the UK markets, each contributing close to USD 4 million in revenue during the same year. Currently, there are no approved therapies specifically for preeclampsia; delivery remains the only definitive cure, while management primarily depends on antihypertensive drugs, anticonvulsants, and corticosteroids.

Antihypertensive treatment continues to be the primary approach in managing preeclampsia. In 2024, these agents contributed approximately USD 50 million to the overall US market value.

In 2025, the 7MM reported approximately 447,000 new cases of preeclampsia. The United States recorded the largest share of diagnosed cases, contributing to more than half of the total across these regions. Within the EU4 and the UK, the highest incidence was observed among women aged 30–34 years, with around 53,000 cases. In the US, late-onset preeclampsia emerged as the most common subtype, accounting for nearly 260,000 cases. Meanwhile, Japan documented about 25,000 new cases during the same year.

In 2025, preeclampsia in the United States is projected to impact around 170,000 individuals with mild forms and approximately 55,000 with severe cases, highlighting the significant burden and variation in severity of this hypertensive pregnancy condition.

DelveInsight’s report, “Preeclampsia Market Insights, Epidemiology, and Market Forecast-2036” provides a comprehensive analysis of the Preeclampsia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Preeclampsia market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Preeclampsia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Preeclampsia Market Forecast

Some of the key facts of the Preeclampsia Market Report:

• The introduction of advanced diagnostic tools, such as BRAHMS PIGF plus KRYPTOR and BRAHMS sFlt-1 KRYPTOR developed by Thermo Fisher Scientific, along with specialized blood tests, is enhancing the prediction and management of preeclampsia.
• At present, the preeclampsia pipeline remains relatively limited, with only a small number of companies involved and most candidates still in the preclinical stage. However, Comanche Biopharma’s CBP-4888 has recently gained momentum after receiving Fast Track Designation (FTD) for preeclampsia.
• Key Preeclampsia Companies: Kyowa Kirin, Gynuity Health, and others
• Key Preeclampsia Therapies: KW-3357, Antithrombin gamma, Nifedipine, and others
• The Preeclampsia epidemiology based on gender analyzed that incidence of pre-eclampsia in a study population is highest for mild cases
• The Preeclampsia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Preeclampsia pipeline products will significantly revolutionize the Preeclampsia market dynamics.

Preeclampsia Overview

Preeclampsia is a serious pregnancy complication characterized by high blood pressure and signs of damage to other organs, often the kidneys and liver. It typically develops after the 20th week of pregnancy and can pose significant risks to both the mother and the baby if not managed properly.

Get a Free sample for the Preeclampsia Market Report:

https://www.delveinsight.com/report-store/preeclampsia-market

Key Trends in Preeclampsia Therapeutics Market:

• Rising focus on early detection and preventive therapeutics: Increasing adoption of biomarker-based screening and predictive diagnostics is enabling earlier intervention, which is driving demand for preventive treatment approaches alongside traditional therapies.
• Growing use of combination therapy and multi-target approaches: Therapeutic strategies are evolving from single-drug regimens (e.g., antihypertensives) to combination treatments targeting multiple pathways such as endothelial dysfunction and inflammation.
• Expansion of hospital-based and integrated care models: Hospitals are adopting multidisciplinary care (obstetricians, cardiologists, neonatologists), supported by advanced monitoring systems, improving outcomes and increasing therapeutic demand.
• Increasing R&D in novel and targeted therapies: Pharmaceutical and biotech companies are investing in innovative drug classes and precision medicine approaches, including therapies targeting placental biology and vascular mechanisms.
• Rising global disease burden and high-risk pregnancies: Growing incidence due to factors like advanced maternal age and comorbidities is expanding the patient pool, thereby accelerating market growth and need for effective therapeutics 

Preeclampsia Epidemiology

The Preeclampsia epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Preeclampsia Epidemiology Segmentation:

The Preeclampsia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of Preeclampsia in the 7MM
• Treated Cases of Preeclampsia in the 7MM
• Total Diagnosed Incident Cases of Preeclampsia in the 7MM
• Severity-specific Incident Cases of Preeclampsia in the 7MM
• Age-specific Incident Cases of Preeclampsia in the 7MM
• Subtype-specific Incident Cases of Preeclampsia in the 7MM

Download the report to understand which factors are driving Preeclampsia epidemiology trends @ Preeclampsia Epidemiology Forecast

Recent Development In The Preeclampsia Treatment Landscape:

• In December 2025, DiaMedica Therapeutics announced significant progress in its DM199 program for treating preeclampsia. Following a successful pre-IND meeting, the FDA requested an additional non-clinical study, with results expected by Q2 2026. Simultaneously, an ongoing Phase 2 investigator-sponsored trial in South Africa has demonstrated promising early safety and efficacy. DM199, a recombinant human tissue kallikrein-1, aims to improve blood flow and reduce blood pressure without crossing the placental barrier. These developments bolster the potential of DM199 as a novel therapeutic for a condition where delivery remains the only current treatment.
• In June 2024, The Company announced the expansion of its DM199 clinical development program to include preeclampsia (PE). PE is a severe pregnancy complication that generally arises after the 20th week of gestation and is marked by high blood pressure and damage to organs, particularly the kidneys and liver. Affecting up to 8% of pregnancies globally, preeclampsia presents substantial risks to both mother and baby, such as the risk of stroke, placental abruption, progression to eclampsia, premature birth, and even death.

Preeclampsia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Preeclampsia market or expected to get launched during the study period. The analysis covers Preeclampsia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Preeclampsia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Preeclampsia Therapies and Key Companies

• KW-3357: Kyowa Kirin
• Antithrombin gamma: Kyowa Kirin Co., Ltd
• Nifedipine: Gynuity Health
• CBP-4888: Comanche Biopharma

Discover more about therapies set to grab major Preeclampsia market share @ Preeclampsia Treatment Market

Preeclampsia Market Drivers

• Rising Maternal Health Concerns: Increasing awareness of maternal morbidity and mortality is driving early diagnosis and treatment adoption.
• Growing Prevalence of Risk Factors: Higher incidence of hypertension, obesity, diabetes, and advanced maternal age is expanding the patient pool.
• Advancements in Diagnostic Technologies: Development of biomarkers (e.g., sFlt-1/PlGF ratio) and improved prenatal screening are enhancing early detection.
• Increasing R&D and Pipeline Activity: Pharmaceutical companies are investing in novel therapeutics targeting angiogenic pathways and placental dysfunction.
• Government and Healthcare Initiatives: Supportive maternal health programs and improved prenatal care infrastructure are boosting market growth.

Preeclampsia Market Barriers

• Limited Approved Therapeutic Options: Current management mainly focuses on symptom control and early delivery rather than disease modification.
• Complex Disease Pathophysiology: Multifactorial nature of preeclampsia makes drug development challenging.
• Regulatory and Clinical Trial Challenges: Ethical concerns in testing drugs during pregnancy can slow clinical progress.
• Underdiagnosis in Low-Resource Settings: Limited access to prenatal care and diagnostic tools restricts market expansion in developing regions.
• High Treatment and Monitoring Costs: Frequent monitoring and hospitalization can create economic burdens, limiting accessibility.

Scope of the Preeclampsia Market Report

• Study Period: 2022–2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Preeclampsia Companies: Kyowa Kirin, Kyowa Kirin Co., Ltd, Gynuity Health, and others
• Key Preeclampsia Therapies: KW-3357, Antithrombin gamma, Nifedipine, and others\
• Preeclampsia Therapeutic Assessment: Preeclampsia current marketed and Preeclampsia emerging therapies
• Preeclampsia Market Dynamics: Preeclampsia market drivers and Preeclampsia market barriers
• Preeclampsia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Preeclampsia Unmet Needs, KOL’s views, Analyst’s views, Preeclampsia Market Access and Reimbursement

To know more about Preeclampsia companies working in the treatment market, visit @ Preeclampsia Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.